References

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

10.1016/s0140-6736(15)61412-x · 2015 · External reference

Seroprevalence of markers for hepatitis B viral infection

10.1016/j.ijid.2010.09.005 · 2011 · External reference

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

10.1002/hep.510310232 · 2000 · External reference

Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy

10.1097/meg.0000000000001130 · 2018 · External reference

Paradoxical HBsAg and anti-HBs coexistence among chronic HBV infections: causes and consequences

10.7150/ijbs.55724 · 2021 · External reference

Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal

10.1016/s0168-8278(98)80017-2 · 1998 · External reference

Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection

10.1097/01.tp.0000151661.52601.fb · 2005 · External reference

Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients

10.1111/jvh.13279 · 2020 · External reference

Presence of hepatitis B surface antibody in addition to hepatitis B core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation

10.1097/tp.0000000000002173 · 2018 · External reference

Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients

10.1097/md.0000000000019407 · 2020 · External reference

Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation

10.1016/j.transproceed.2012.03.040 · 2012 · External reference

Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area

10.1016/s1053-2498(01)00280-7 · 2001 · External reference

Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice

10.1111/ctr.13514 · 2019 · External reference

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study

10.1186/s13075-018-1748-z · 2018 · External reference

Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients

10.1111/tid.13009 · 2019 · External reference

Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection

10.1086/513200 · 2007 · External reference

Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion

10.1016/j.jhep.2022.07.003 · 2022 · External reference

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

10.1053/j.gastro.2014.10.039 · 2015 · External reference

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

10.1016/j.jhep.2017.03.021 · 2017 · External reference

KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation

10.1097/tp.0000000000003136 · 2020 · External reference

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

10.1016/j.jhep.2019.03.034 · 2019 · External reference

Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure

10.1002/hep.24109 · 2011 · External reference

Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018

10.1001/jamanetworkopen.2021.44521 · 2022 · External reference